Hanx Biopharmaceuticals (Wuhan) Co., Ltd. completed an on-market repurchase of 26,500 H-shares on 19 May 2026. The shares were bought at prices ranging from HKD 29.00 to HKD 30.50, translating into a volume-weighted average cost of HKD 29.60 per share and a total cash outlay of approximately HKD 0.78 million.

Following the transaction, the number of shares held as treasury stock increased to 709,000, while the company’s issued share capital excluding treasury shares declined to 135.51 million. Total issued shares remained unchanged at 136.22 million, making the latest buyback equivalent to 0.02% of the outstanding shares prior to the repurchase.

The purchase forms part of the mandate approved on 12 February 2026, which authorises the company to repurchase up to 13.62 million shares. Cumulative buybacks under this mandate now stand at 709,000 shares, representing 0.52% of the authorised limit.

Under Hong Kong Exchange rules, Hanx Biopharmaceuticals is subject to a moratorium on issuing new shares or disposing of treasury shares until 18 June 2026.